Nrx pharmaceuticals announces first successful commercial formulation for zyesami™ (aviptadil), enabling volume manufacture, shipping, and stockpiling of covid-19 medication subject to regulatory approval

Radnor, pa., july 22, 2021 /prnewswire/ -- nrx pharmaceuticals (nrx) (nasdaq: nrxp) announced today it has validated the first commercial formulation of zyesami™ (aviptadil) for intravenous use, allowing for high volume manufacture, with an anticipated one year or greater stability, under appropriate storage conditions.
NRXP Ratings Summary
NRXP Quant Ranking